AlphaGrep UK
CRSP icon

AlphaGrep UK’s CRISPR Therapeutics CRSP Stock Holding History

AlphaGrep UK’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$249K Buy
4,495
+102
+2% +$5.5K 0.07% 586
2026
Q2 		$240K Buy
+4,393
New +$232K 0.07% 609

Other funds holding CRSP

ARK Investment Management
ARK Investment Management St. Petersburg, Florida $17.4B AUM 41.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
GSK plc
GSK plc London $497M AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Nikko Asset Management Americas
Nikko Asset Management Americas New York $8.04B AUM 33.34% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return

AlphaGrep UK's CRSP Position: Q3 2026 in Review

AlphaGrep UK increased its CRISPR Therapeutics (CRSP) stake by 2.3% in Q3 2026, buying an estimated $5.5K and bringing the position to 4,495 shares worth $249K. The position accounts for 0.07% of the portfolio, ranked #586.

AlphaGrep UK first reported a position in CRSP in Q2 2026 and has held it in 2 quarters since. 413 funds tracked by Wall St. Rank hold CRSP as of Q3 2026.

  • AlphaGrep UK held 4,495 shares of CRISPR Therapeutics worth $249K as of Q3 2026.
  • AlphaGrep UK bought 102 CRISPR Therapeutics shares in Q3 2026, an estimated $5.5K.
  • CRISPR Therapeutics made up 0.07% of AlphaGrep UK's portfolio in Q3 2026, its #586 holding.
  • AlphaGrep UK first reported a position in CRISPR Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • 413 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2026.

Based on AlphaGrep UK's 13F filing for Q3 2026, filed 12 Nov 2026.